Stock Ratings / Health Care / NTLA / financials

CLDX (41) NEOG (52) QDEL (30) ACHV (44) ⌘ Pro Terminal →

Intellia Therapeutics Inc. (NTLA) Revenue-to-Profit Sankey Flow & SEC XBRL Financials

$13.23 -0.68% NASDAQ • Live Quote vs Prior Daily Close (Synced Snapshot) EXT / AFTER-HRS: $13.19

Intellia Therapeutics Inc. (NTLA) carries a Roarable Rating of E (Strong Sell) with 33/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.

📊 Historical Track Record Warning: Scores below 50 (33/100 · E) historically underperformed SPY in 71% of rolling 90-day windows →

ROARABLE E • RED ALERT Cap $1.85B

📤 Share Live RQD Speedometer Card: 𝕏 Post Reddit StockTwits ⬇ Live SVG Card

INTERACTIVE SCENARIO DECK:

🛡️ Portfolio Crash X-Ray

EXT / AFTER-HRS: $13.19 (-0.31%)🧬 Dilution Drag (+2.48% YoY Shares)⚙️ Cash Engine: 3/20 (E) • 0% FCF Margin

Verify 90D Bucket Audit →

📊 Historical Track Record Warning: Scores below 50 (33/100 · E) historically underperformed SPY in 71% of rolling 90-day windows (-8.9% avg 90D alpha vs SPY • 29.0% hit rate).

Audit Bucket Track Record →

RQD QUANT TACHOMETERRED ALERT • E

3-of-3 JEV AI Jury Bearish Warning

Cash

SEC

Whale

Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer

5-PILLAR SNOWFLAKE RADARRw E · Rk D

Each axis scored 0–20

12M PRICE TARGET CONE-11.3% Base Target

WHALE OPTIONS SNAPSHOT: — (No Active Options Snapshot on file for NTLA)Realized 20D OHLCV Swing Band: ±12.5%

Deterministic 5-Pillar Attribution (33/100 Composite)

🔍 WHY NTLA SCORES 33/100 (E) — TOP 3 DRIVERS2 Bullish Pillars + #1 Risk Drag

▲ #1 Bullish Driver: Whale & Options Positioning+10/20 pts (30% of score)

20D Institutional Volume Accumulation (±12.5% realized swing band)

▲ #2 Bullish Driver: Macro Regime Fit+10/20 pts (30% of score)

FRED Regime × Technicals: 50% of 52W Range • RSI-14 at 53.4 (NEUTRAL RANGE)

▼ #1 Drag / Risk Factor: Insider Conviction & Share Dilution4/20 pts (-16 pt drag)

Dilution Drag (+2.48% YoY Shares) & executive Form 4 sales trim 16 pts from alignment

📈 PAST 4 QUARTERS RQD vs SUBSEQUENT RETURNQ1 → Q2 → Q3 → Current

Q1 (-3Q)

Grade E$13.07-12.6% Next Q

Q2 (-2Q)

Grade E$11.42-1.8% Next Q

Q3 (-1Q)

Grade E$11.21+18% Next Q

Current

Grade E$13.23-8.9% Hist 90D α

Trajectory: E (25) → E (33)Full Audit →

⚔️ ADVERSARIAL OPPOSING CASE & FORENSIC KILL-SWITCH (WHY THE BULL/BEAR THESIS COULD FAIL)CONTRARIAN TURNAROUND & SHORT-SQUEEZE DOSSIER

⚔️ Adversarial Opposing Case: What Could Spark a NTLA Turnaround Squeeze

Gideon Ashmere Forensic Desk →

While NTLA currently carries a cautious 33/100 (E) rating due to Insider Conviction & Share Dilution (4/20), shorts face asymmetric squeeze risk if free cash flow inflects or management executes accretive buybacks.

🚀 Contrarian Squeeze Trigger #1

Established market leader in Health Care with deep daily trading liquidity.

🚀 Contrarian Squeeze Trigger #2

Options & Short-Covering Gamma: Reclaiming the 50-day SMA ($12.23) and Max Pain ($13.89) forces dealer call-delta covering toward $19.40.

🚀 Contrarian Squeeze Trigger #3

Forensic Repair Trigger: Halting share dilution (Dilution Drag (+2.48% YoY Shares)) or retiring high-cost debt immediately upgrades the SEC 10-K Forensic pillar.

🎲 LIVE PREDICTION MARKET ODDS TIED TO $NTLA• $2.4M Crowd Pool • Kalshi / Polymarket Composite

Contract: “NTLA Beats Next Quarter EPS Consensus (Dec 30, 2026) & Holds Above 200D SMA”

YES 33%NO 67%Trade / Inspect Odds →

VISUAL REVENUE-TO-PROFIT SANKEY WATERFALL • FY 2025 (10-K)

How NTLA Turns Every Dollar of Sales Into Real Bottom-Line Profit

Free Cash Flow:$0 (0% FCF Margin)

Multi-Year SEC EDGAR XBRL Revenue, Net Profit & Free Cash Flow Trajectory

■ Revenue■ Net Profit■ Free Cash Flow

FY23

Rev $36.3M

FY24

Rev $57.9M

FY25

Rev $67.7M

Fiscal Year	Revenue	Gross Margin	Op Margin	Net Profit	Free Cash Flow	ROIC %
FY 2025	$67.7M	52%	-80%	-$412.7M	-$395.9M	-45%
FY 2024	$57.9M	52%	-80%	-$519.0M	-$354.7M	-45%
FY 2023	$36.3M	52%	-80%	-$481.2M	-$394.1M	-35%

ON-DEMAND RQD QUANT WORKSHOP • SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher & Roarable Forensic Quant Desk

Red-Light Warning Desk: Spotting SEC Cash-Flow & Dilution Risks Before Downgrades (Featuring NTLA)

✓Walkthrough of NTLA's RQD Radar, SEC cash-conversion gap & downside invalidation levels
✓3 asymmetric Bear/Hedge frameworks when 10-year Treasury yields stay elevated
✓Includes nightly RQD rating-change & forensic signal email alerts on your tracked stocks

RQD INSIDER CLUB WAITLIST$49/YR PLANNED

Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?

Join Founding VIP Waitlist (No Card Required) →$100K Arena

NTLA // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: -1.85%▲ RESISTANCE BREAKOUT

2026-10-30O $12.88H $13.23L $12.04C $13.23VOL 4.08M

RES: $13.05SUP: $10.61SMA50: $12.23SMA200: $13.08

PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK

NTLA Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure

🦋 NTLA Butterfly Map → + Track NTLA →

Share Count & Dilution Monitor (#25)

Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).

Reverse-DCF Expectations Hurdle (#30)

8.0%/yr Implied 5Y Growth

vs. +16.9% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).

Ellis Vennor Setup Ledger (#33)

No active Ellis Vennor swing setup published on NTLA today. View full Setup Ledger →

🦋 Documented & Second-Order Butterfly Connections Open Graph →

No direct multi-tier Butterfly edges indexed yet for NTLA. Explore sector supply chains on /butterfly.

AI Analyst Theses, Washington Policy & Company Video

🎬 No recent verified company-specific video clip queued for NTLA today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk →

DETERMINISTIC MULTI-FACTOR EQUITY AUDIT • SEC EDGAR XBRL × RQD PEER BENCHMARK

📊 Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (NTLA)

Health Care Rank #858 of 1016 ⚔️ CLDX vs NTLA Full Matrix →

1. Head-to-Head Health Care Peer Comparison (NTLA vs. CLDX, NEOG, QDEL, ACHV)

Industry: Biotechnology: In Vitro & In Vivo Diagnostic Substances (18 Tracked Issuers)

Across 1016 tracked Health Care securities in the Roarable RQD universe, Intellia Therapeutics Inc. (NTLA) ranks #858 by composite RQD confidence (33/100, grade E) and #277 by equity capitalization ($1.85B). Within this direct 5-issuer industry benchmark cohort, NTLA leads on earnings valuation at N/A trailing P/E, while NEOG leads on capital efficiency and profitability with -0.6% ROIC and 46.9% gross margin. NEOG currently holds the highest overall quantitative score in the immediate peer group at 52/100 (D+) compared with NTLA at 33/100 (E).

Ticker / Company	Roarable Grade	RQD Score	Trailing P/E	Gross Margin	ROIC	1D Change	Market Cap	Head-to-Head
NTLA ACTIVE Intellia Therapeutics Inc.	E	33/100	—	—	-35.0%	-0.68%	$1.85B	Benchmark Subject
CLDX Celldex Therapeutics Inc.	D-	41/100	—	87.1%	-35.0%	+0.78%	$2.35B	/cldx-vs-ntla →
NEOG Neogen Corporation	D+	52/100	—	46.9%	-0.6%	+1.16%	$2.68B	/neog-vs-ntla →
QDEL QuidelOrtho Corporation	E	30/100	—	—	-35.0%	-1.78%	$943.6M	/qdel-vs-ntla →
ACHV Achieve Life Sciences Inc.	D	44/100	—	—	-35.0%	+4.96%	$739.9M	/achv-vs-ntla →

2. Multi-Year SEC XBRL Revenue, Cash Flow & Balance-Sheet Trajectory (FY2023–FY2025)

SEC EDGAR 10-K • FILED 2025-12-31 • CIK 0001652130

In its most recent audited fiscal period (FY2025, filed 2025-12-31), Intellia Therapeutics Inc. (NTLA) reported GAAP revenue of $67.7M (+16.9% vs. FY2024 revenue of $57.9M , and +86.5% cumulative change since FY2023) , GAAP net income of -$412.7M, operating cash flow of -$394.7M, and free cash flow of -$395.9M (-11.6% YoY). On the balance sheet, NTLA closed FY2025 with $842.1M in total assets against $0 in total debt (Altman Z-Score: 1.17, Piotroski F-Score: 4/9).

Fiscal Period	Filing Date	Revenue	Net Income	Operating Cash Flow	Free Cash Flow	Total Assets	Total Debt
FY2025 (FY)	2025-12-31	$67.7M	-$412.7M	-$394.7M	-$395.9M	$842.1M	—
FY2024 (FY)	2024-12-31	$57.9M	-$519.0M	-$348.9M	-$354.7M	$1.19B	—
FY2023 (FY)	2023-12-31	$36.3M	-$481.2M	-$394.1M	-$394.1M	—	—

3. NTLA Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)

✓ SCHEMA.ORG FAQPAGE JSON-LD ENABLED

Is NTLA stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

As of 2026-11-01, Intellia Therapeutics Inc. (NASDAQ: NTLA) is rated E (Strong Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 33/100 at a spot price of $13.23 (-0.68% 1D, market cap $1.85B). Pillar breakdown: Fundamental Cash Engine 3/20, Institutional 13F & Options Flow 10/20, Executive Insider Alignment 8/20, FRED Macro Regime Fit 10/20, and SEC Balance-Sheet Forensics 3/20. Across 1016 tracked Health Care issuers, NTLA ranks #858 in composite RQD confidence.

How does NTLA compare to CLDX and NEOG in the Health Care sector?

Within the Health Care sector (Biotechnology: In Vitro & In Vivo Diagnostic Substances), NTLA carries a Roarable E (33/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of -35.0%. By comparison, CLDX (Celldex Therapeutics Inc.) holds a D- grade (41/100 RQD, P/E N/A, ROIC -35.0%, cap $2.35B) and NEOG (Neogen Corporation) posts a D+ grade (52/100 RQD, P/E N/A, ROIC -0.6%, cap $2.68B). Among the 5-stock peer group, NTLA leads on earnings multiple (N/A) while NEOG leads on capital efficiency (-0.6% ROIC).

What are the biggest fundamental strengths and SEC risk factors for NTLA?

Per NTLA's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001652130), Intellia Therapeutics Inc. generated $67.7M in revenue (+16.9% YoY), -$412.7M in net income, and -$395.9M in free cash flow against $842.1M in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity.. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately.. Institutional options positioning shows a 50% call / 50% put premium split.

Where is NTLA trading relative to its 50-day, 200-day, and 52-week technical levels?

NTLA last traded at $13.23 (-0.68% on volume of 4,703,882 shares), positioning the stock +8.18% above its 50-day simple moving average ($12.23) and +1.15% above its 200-day simple moving average ($13.08). Across its 52-week range of $7.95 to $18.48, NTLA sits at the 50.1% percentile with a 14-day RSI of 53.4 (NEUTRAL RANGE) and an implied next-earnings move of ±12.5% ($11.58 to $14.88).

NTLA Investor FAQ & Complete 8-Part Research Index

100% OPEN ACCESS • SEC EDGAR × CBOE × FRED

How profitable is Intellia Therapeutics Inc. (NTLA)?

In FY 2025 (10-K), NTLA converted $67.7M of revenue into a 52% gross margin, 0% operating margin, and $0 in free cash flow (0% FCF margin).

Direct Sub-Reports: NTLA RQD Cockpit NTLA 12M Forecast NTLA Earnings & Move NTLA Dividends & DRIP NTLA Insiders & 13F NTLA Whale Options NTLA Profit Sankey NTLA News & Why